Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 5, 2015
SOLANA BEACH, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market. Evoke will hol...
Oct 7, 2015
SOLANA BEACH, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility") to extend the interest-only payment term for an additional 1...
Sep 28, 2015
SOLANA BEACH, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached a key milestone under its $4.5 million loan and security agreement (the credit facility) with Square 1 Bank (Square 1). A...
Sep 15, 2015
SOLANA BEACH, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its Phase 3 clinical trial design for EVK-001 (metoclopramide nasal spray) is consistent with the FDA's recommendations in the recently released ...
Aug 18, 2015
SOLANA BEACH, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's concurrence with the Company's proposed pediatric stud...
Aug 13, 2015
Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke's Phase 3 clinical trial protocol design SOLANA BEACH, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for ...
Jul 30, 2015
SOLANA BEACH, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13, 2015, after the close of the market. Evoke will...
Jul 1, 2015
SOLANA BEACH, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, July 8, 2015 at 10:15 AM ET at the Cantor Fitzgerald Inaugural Healthcare Conference. The conference is being held on J...
Jun 24, 2015
SOLANA BEACH, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that previously disclosed results from its Phase 2b clinical trial evaluating EVK-001, its patented intranasal delivery formulation of metoclopramide f...
May 14, 2015
SOLANA BEACH, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2015. Dave Gonyer, R.Ph., President and CEO, stated, "We continue to make important ...
Apr 30, 2015
SOLANA BEACH, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter of 2015 on Thursday, May 14, 2015, after the close of the market. Evoke will hold a...
Apr 14, 2015
SOLANA BEACH, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed the production of a commercial scale lot of EVK-001 as required by the U.S. Food and Drug Administration (FDA). With the...
Apr 9, 2015
SOLANA BEACH, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the European Patent Office has granted the Company European Union (EU) patent no. 2376075 for its lead product candidate, EVK-001. This patent is ...
Mar 4, 2015
SOLANA BEACH, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, March 11, 2015 at 10:00AM PT at the 27th Annual ROTH Conference. The conference is being held March 8-11 at the Ritz-C...
Mar 4, 2015
SOLANA BEACH, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2014. Dave Gonyer, R.Ph., President and CEO, stated, "By achieving two sig...
= add release to Briefcase